急性腎障害(AKI)治療薬市場:パイプライン分析・治験・特許・指定・協力・動向

調査会社P&S Market Research社が発行したリサーチレポート(データ管理コード:PSM804017)
◆英語タイトル:Acute Kidney Injury (AKI) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
◆発行会社/調査会社:P&S Market Research
◆商品コード:PSM804017
◆発行日:2018年2月
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆ページ数:151
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD3,250 ⇒換算¥351,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,750 ⇒換算¥837,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
P&S Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[急性腎障害(AKI)治療薬市場:パイプライン分析・治験・特許・指定・協力・動向]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Acute kidney injury (AKI) or acute kidney failure is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys. AKI is different from chronic kidney disease, wherein the kidney function is lost over a period of time. The disease generally occurs as a complication of another serious disease and is more common in the geriatric population that suffers from various other diseases. The study analyzed that AKI therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.
Insights on Pipeline Segments

According to the research findings, a majority of the drug candidates for the treatment of AKI are being developed to be administered by the intravenous route. It has been observed that the drugs which are being administered through intravenous route have high efficacy because of their higher bioavailability.

AKI Therapeutics Pipeline has been Witnessing Significant Growth due to Increasing Research Funding

Various health organizations such as National Institute of Diabetes and Digestive and Kidney Diseases and Small Business Innovation Research (SBIR) program of the U.S. Small Business Administration (SBA) are strengthening the growth of AKI therapeutics pipeline. For instance, TheraSource LLC received a funding of $335,318 from SBIR for its research project aimed at demonstrating the feasibility of developing recombinant human milk fat globule epidermal growth factor rhMFG E, as a novel and effective therapeutic for treating patients suffering with AKI, associated with ischemia due to low renal perfusion.

Increase in Patents Approval for AKI therapeutics Candidates

There has been an increase in the number of patents approved for the development of drug candidates for the treatment of AKI. For instance, in October 2016, the USPTO issued U.S. Patent 9,464,114 to Arch BioPartners, entitled, “Peptides that Block Leukocyte Recruitment and Methods of Use”. This was the first patent issued protecting the composition and method of use for Metablok.

AKI Therapeutics Pipeline Marked by Various Technological Advancements

Most of the companies are developing innovative technologies for the synthesis or production of drug candidates for the treatment of AKI. For instance, Quark Pharmaceuticals Inc. is using an innovative technology platform for generation of chemically modified siRNA compounds and their delivery to the desired organs. These are particularly well-suited to exploit the potential of siRNA for therapeutic applications. Also, Silver Creek Pharmaceuticals Inc. is using smart growth factor technology platform for the development of growth factors that play an important role in development, maintenance of tissue homeostasis, and pathology of many disease states.

Some of the key players involved in the development of AKI therapeutics include Alloksys Life Sciences B.V., Stealth BioTherapeutics Inc., and Angion Biomedica Corp.

*** レポート目次(コンテンツ)***

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Disease Overview

4.1.1 Classification of AKI

4.1.1.1 General classification

4.1.1.2 Classification based on daily urine excretion

4.1.1.3 RIFLE classification system for AKI

4.1.1.4 AKI network classification system

4.2 Causes and Risk Factors

4.2.1 Causes of AKI

4.2.1.1 Reduced blood flow to kidneys

4.2.1.2 Damage to kidneys

4.2.1.3 Obstruction to the drainage of kidneys

4.2.2 Risk Factors of AKI

4.3 Symptoms

4.3.1 Complications

4.4 Diagnosis

4.5 Treatment

4.5.1 Treatment of the Underlying Cause of AKI

4.5.2 Treatment of Symptoms/Complications Associated with AKI

4.6 Prevention

4.7 Epidemiology

4.8 Key Drivers

4.8.1 Research Funding from Various Agencies

4.8.2 No Approved Treatment

4.9 Key Barriers

4.9.1 Discontinuation of Drugs

4.10 Acute Kidney Injury Therapeutics Pipeline Analysis

4.10.1 Pipeline Analysis by Phase

4.10.2 Pipeline Analysis by Molecule Type

4.10.3 Pipeline Analysis by Route of Administration

4.10.4 Pipeline Analysis by Company

Chapter 5. Acute Kidney Injury Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase III

5.1.1 RESCAP

5.1.1.1 Clinical trials

5.1.1.2 Grant

5.1.1.3 Patents

5.1.2 XXXX

5.1.2.1 Clinical trials

5.2 Phase II/III

5.2.1 Levosimendan

5.2.1.1 Clinical trials

5.2.2 XXXX

5.2.2.1 Clinical trials

5.3 Phase II

5.3.1 Elamipretide

5.3.1.1 Collaboration

5.3.1.2 Technology

5.3.2 XXXX

5.3.2.1 Clinical trials

5.3.3 XXXX

5.3.3.1 Pre-Clinical results

5.3.3.2 Clinical trials

5.3.4 XXXX

5.3.4.1 Clinical trials

5.3.4.2 Funding

5.3.5 XXXX

5.3.5.1 Pre-Clinical results

5.3.5.2 Clinical trials

5.3.5.3 Technology

5.3.6 XXXX

5.3.6.1 Clinical trials

5.3.6.2 Clinical trial results

5.3.6.3 Pre-Clinical results

5.3.6.4 Funding

5.3.6.5 Strategic developments

5.3.7 XXXX

5.3.7.1 Clinical trials

5.3.7.2 Clinical trial results

5.3.7.3 Strategic developments

5.3.8 XXXX

5.3.8.1 Clinical trials

5.4 Phase I/II

5.4.1 SBI-101

5.4.1.1 Clinical trials

5.4.1.2 Grants

5.5 Phase I

5.5.1 XXXX

5.5.1.1 Clinical trials

5.5.1.2 Clinical trial results

5.5.1.3 Technology

5.5.2 XXXX

5.5.3 XXXX

5.5.3.1 Clinical trials

5.5.4 XXXX

5.5.4.1 Pre-Clinical result

5.5.4.2 Clinical trials

5.5.4.3 Strategic developments

5.6 IND

5.6.1 XXXX

5.6.1.1 Pre-Clinical results

5.6.1.2 Patent

5.6.1.3 Technology

5.6.1.4 Strategic developments

5.7 Pre-Clinical

5.7.1 XXXX

5.7.1.1 Pre-Clinical results

5.7.1.2 Clinical trials

5.7.1.3 Collaboration

5.7.1.4 Patent

5.7.2 XXXX

5.7.2.1 Technology

5.7.3 XXXX

5.7.3.1 Technology

5.7.4 XXXX

5.7.4.1 Strategic developments

5.7.5 XXXX

5.7.5.1 Pre-Clinical results

5.7.6 XXXX

5.7.6.1 Strategic developments

5.7.7 XXXX

5.7.7.1 Pre- Clinical study

5.7.8 XXXX

5.7.8.1 Pre-Clinical trials

5.7.8.2 Patents

5.7.8.3 Other

5.7.9 XXXX

5.7.9.1 Pre-Clinical Result

5.7.10 XXXX

5.7.10.1 Patents

5.7.10.2 Technology

5.7.10.3 Strategic developments

5.7.11 XXXX

5.7.11.1 Pre-Clinical results

5.7.11.2 Strategic developments

5.7.12 XXXX

5.7.12.1 Pre-Clinical study

5.7.13 XXXX

5.7.13.1 Pre-Clinical result

5.7.14 XXXX

5.7.14.1 Pre-Clinical results

5.7.14.2 Technology

5.7.15 XXXX

5.7.16 XXXX

5.7.16.1 Pre-Clinical results

5.7.17 XXXX

5.7.17.1 Pre-Clinical results

5.7.18 XXXX

5.7.18.1 Pre-Clinical result

5.8 Discovery

5.8.1 XXXX

5.8.2 XXXX

5.8.2.1 Strategic developments

5.8.3 XXXX

5.8.3.1 Patents

5.9 Unknown

5.9.1 XXXX

5.9.1.1 Strategic developments

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for AKI Therapeutics Pipeline

7.2 SWOT Analysis of AKI Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Angion Biomedica Corp.

8.1.1 Business Overview

8.1.2 Product & Service Offerings

8.2 Company 2

8.2.1 Business Overview

8.2.2 Product & Service Offerings

8.3 Company 3

8.3.1 Business Overview

8.3.2 Product & Service Offerings

8.4 Company 4

8.4.1 Business Overview

8.4.2 Product & Service Offerings

8.5 Company 5

8.5.1 Business Overview

8.5.2 Product & Service Offerings

8.6 Company 6

8.6.1 Business Overview

8.6.2 Product & Service Offerings

8.7 Company 7

8.7.1 Business Overview

8.7.2 Product & Service Offerings

8.8 Company 8

8.8.1 Business Overview

8.8.2 Product & Service Offerings

8.9 Company 9

8.9.1 Business Overview

8.9.2 Product & Service Offerings

8.1 Company 10

8.10.1 Business Overview

8.10.2 Product & Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

LIST OF TABLES

TABLE 1 GENERAL CLASSIFICATION OF AKI

TABLE 2 CLASSIFICATION OF AKI BASED ON DAILY URINE EXCRETION

TABLE 3 STAGES OF AKI UNDER RIFLE CLASSIFICATION SYSTEM

TABLE 4 STAGES OF AKI UNDER AKIN CLASSIFICATION SYSTEM

TABLE 5 PIPELINE ANALYSIS OF AKI THERAPEUTICS, BY COMPANY (2018)

TABLE 6 DESCRIPTION OF RESCAP

TABLE 7 CLINICAL TRIALS OF RESCAP

TABLE 8 DESCRIPTION OF XXXX

TABLE 9 CLINICAL TRIALS OF XXXX

TABLE 10 DESCRIPTION OF LEVOSIMENDAN

TABLE 11 CLINICAL TRIALS OF LEVOSIMENDAN

TABLE 12 DESCRIPTION OF XXXX

TABLE 13 CLINICAL TRIALS OF XXXX

TABLE 14 DESCRIPTION OF ELAMIPRETIDE

TABLE 15 DESCRIPTION OF XXXX

TABLE 16 CLINICAL TRIALS OF XXXX

TABLE 17 DESCRIPTION OF XXXX

TABLE 18 CLINICAL TRIALS OF XXXX

TABLE 19 DESCRIPTION OF XXXX

TABLE 20 CLINICAL TRIALS OF XXXX

TABLE 21 DESCRIPTION OF XXXX

TABLE 22 CLINICAL TRIALS OF XXXX

TABLE 23 DESCRIPTION OF XXXX

TABLE 24 CLINICAL TRIALS OF XXXX

TABLE 25 DESCRIPTION OF XXXX

TABLE 26 CLINICAL TRIALS OF XXXX

TABLE 27 DESCRIPTION OF XXXX

TABLE 28 CLINICAL TRIALS OF XXXX

TABLE 29 DESCRIPTION OF SBI- 101

TABLE 30 CLINICAL TRIALS OF SBI-101

TABLE 31 DESCRIPTION OF XXXX

TABLE 32 CLINICAL TRIALS OF XXXX

TABLE 33 DESCRIPTION OF XXXX

TABLE 34 DESCRIPTION OF XXXX

TABLE 35 CLINICAL TRIALS OF XXXX

TABLE 36 DESCRIPTION OF XXXX

TABLE 37 DESCRIPTION OF XXXX

TABLE 38 DESCRIPTION OF XXXX

TABLE 39 DESCRIPTION OF XXXX

TABLE 40 DESCRIPTION OF XXXX

TABLE 41 DESCRIPTION OF XXXX

TABLE 42 DESCRIPTION OF XXXX

TABLE 43 DESCRIPTION OF XXXX

TABLE 44 DESCRIPTION OF XXXX

TABLE 45 DESCRIPTION OF XXXX

TABLE 46 DESCRIPTION OF XXXX

TABLE 47 DESCRIPTION OF XXXX

TABLE 48 DESCRIPTION OF XXXX

TABLE 49 DESCRIPTION OF XXXX

TABLE 50 DESCRIPTION OF XXXX

TABLE 51 DESCRIPTION OF XXXX

TABLE 52 DESCRIPTION OF XXXX

TABLE 53 DESCRIPTION OF XXXX

TABLE 54 DESCRIPTION OF XXXX

TABLE 55 DESCRIPTION OF XXXX

TABLE 56 DESCRIPTION OF XXXX

TABLE 57 DESCRIPTION OF XXXX

TABLE 58 DESCRIPTION OF XXXX

TABLE 59 DESCRIPTION OF XXXX

TABLE 60 ANGION BIOMEDICA CORP. – AT A GLANCE

TABLE 61 COMPANY 2 – AT A GLANCE

TABLE 62 COMPANY 3 – AT A GLANCE

TABLE 63 COMPANY 4 – AT A GLANCE

TABLE 64 COMPANY 5 – AT A GLANCE

TABLE 65 COMPANY 6 – AT A GLANCE

TABLE 66 COMPANY 7 – AT A GLANCE

TABLE 67 COMPANY 8 – AT A GLANCE

TABLE 68 COMPANY 9 – AT A GLANCE

TABLE 69 COMPANY 10 – AT A GLANCE

LIST OF FIGURES

FIG 1: RESEARCH METHODOLOGY

FIG 2: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3: BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE

FIG 4: GENERAL CLASSIICATION OF AKI

FIG 5: CLINICAL DIAGNOSIS OF AKI

FIG 6: TREATMENT ALGORITHM FOR AKI

FIG 7: AKI DRUG CANDIDATES IN DEVELOPMENT (2018)

FIG 8: AKI PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 9: AKI PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 10: BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 11: BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 12: KEY PLAYERS BENCHMARKING

FIG 13: SWOT ANALYSIS



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(PSM804017 )"急性腎障害(AKI)治療薬市場:パイプライン分析・治験・特許・指定・協力・動向" (英文:Acute Kidney Injury (AKI) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments)はP&S Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。